A Phase 3 interventional study of Aripiprazole Lauroxil and Paliperidone Palmitate in Schizophrenia, sponsored by Alkermes, Inc.. Completed at 16 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2020-08-11.
Sponsored by Alkermes, Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing aripiprazole lauroxil in Schizophrenia — none open to participants now, none under way, none of them phase 3. aripiprazole lauroxil · Schizophrenia.
Among the 10 studies testing aripiprazole lauroxil in Schizophrenia, this one is the 4th largest by enrollment, is the only one that started in 2017, is one of 4 in phase 3, and was the 8th registered.
3,567 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.
Browse Schizophrenia studies →None of the 10 studies testing aripiprazole lauroxil in Schizophrenia is open now. The open studies under Schizophrenia, anywhere →
aripiprazole lauroxil: first FDA approval 2015 (ARISTADA). What it is approved for, and how studies give it, is on its page →
Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 1 started in 2017.
This study's enrollment of 200 is above the median of 70 across 2,951 interventional studies indexed under Schizophrenia.
Median enrollment 114 across the 10 interventional studies. Of the 10 that completed or were terminated, 7 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 10 have an industry lead sponsor. The 3 most frequent:
Alkermes, Inc. is the lead sponsor of 83 studies on the registry; 9 are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 5 (56%) have results posted.
21 studies in Schizophrenia by Alkermes, Inc.: 2 open now, 2 under way, 2 of them phase 3. Of 18 finished, 13 (72%) have results posted.
Among the 21 studies in Schizophrenia by Alkermes, Inc., this one is the 14th largest by enrollment of the 19 interventional ones that give a count, is one of 3 that started in 2017, is one of 12 in phase 3, and was the 17th registered.
Alkermes, Inc.’s Schizophrenia studies by the year they started, since 2011.
None of the studies under way reaches primary completion within a year.
Among the 10 studies testing aripiprazole lauroxil in Schizophrenia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Alkermes, Inc.’s 21 in Schizophrenia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will evaluate the efficacy of initiating treatment of schizophrenia with ARISTADA INITIO plus 30 mg oral aripiprazole followed by a 2-month dose of AL.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Regular injections
Combination Product: Aripiprazole Lauroxil
Regular injections
Drug: Paliperidone Palmitate
Intramuscular injection; study drug provided using a pre-filled syringe
Also known as: ARISTADA, ARISTADA INITIO
Intramuscular injection
Also known as: Invega Sustenna
Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score at Week 4
Change within treatment groups of Positive and Negative Syndrome Scale (PANSS) total score between baseline and week 4 based on the observed data without imputation for missing data. The PANSS scale contains 30 questions, each containing an answer range of 1-7. A total PANSS score can range from between 30 to 210; a higher score indicates a worse disease condition.
Time frame: Baseline and 4 weeks
Least Squares Mean Change in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 4
Least squares mean change in Positive and Negative Syndrome Scale (PANSS) between at 4 weeks from Mixed Models Repeated Measures (MMRM). The PANSS scale contains 30 questions, each containing an answer range of 1-7. A total PANSS score can range from between 30 to 210; a higher score indicates a worse disease condition
Time frame: Baseline and 4 weeks
Change in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 9
Change within treatment groups from baseline Positive and Negative Syndrome Scale (PANSS) and 9 weeks based on the observed data without imputation for missing data. The PANSS scale contains 30 questions, each containing an answer range of 1-7. A total PANSS score can range from between 30 to 210; a higher score indicates a worse disease condition.
Time frame: Baseline and 9 weeks
Change in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 25
Change within treatment groups at baseline Positive and Negative Syndrome Scale (PANSS) and at 25 weeks based on the observed data without imputation for missing data. The PANSS scale contains 30 questions, each containing an answer range of 1-7. A total PANSS score can range from between 30 to 210; a higher score indicates a worse disease condition
Time frame: Baseline and 25 weeks
Least Squares Mean Change in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 9
Least squares mean change from baseline Positive and Negative Syndrome Scale (PANSS) and 9 weeks from Mixed Models Repeated Measures (MMRM).The PANSS scale contains 30 questions, each containing an answer range of 1-7. A total PANSS score can range from between 30 to 210; a higher score indicates a worse disease condition
Time frame: Baseline and 9 weeks
Least Squares Mean Change in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 25
Least squares mean change in Positive and Negative Syndrome Scale (PANSS) total score at week 25 from Mixed Models Repeated Measures. The PANSS scale contains 30 questions, each containing an answer range of 1-7. A total PANSS score can range from between 30 to 210; a higher score indicates a worse disease condition
Time frame: Baseline and 25 weeks
Number of Participants With Serious and Non-serious Adverse Events (AEs)
Time frame: Up to 25 weeks
| Milestone | Aripiprazole Lauroxil | Paliperidone Palmitate |
|---|---|---|
| Started | 99 | 101 |
| Completed | 56 | 43 |
| Not completed | 43 | 58 |
| Withdrew: Withdrawal by subject | 20 | 31 |
| Withdrew: Adverse event | 10 | 11 |
| Withdrew: Lost to follow-up | 8 | 9 |
| Withdrew: Lack of efficacy | 4 | 2 |
| Withdrew: Protocol violation | 1 | 3 |
| Withdrew: Physician decision | 0 | 2 |
Change within treatment groups of Positive and Negative Syndrome Scale (PANSS) total score between baseline and week 4 based on the observed data without imputation for missing data. The PANSS scale contains 30 questions, each containing an answer range of 1-7. A total PANSS score can range from between 30 to 210; a higher score indicates a worse disease condition.
| units on a scale | Aripiprazole Lauroxil | Paliperidone Palmitate |
|---|---|---|
| Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score at Week 4 | -17.4 ± 11.57 | -20.1 ± 13.72 |
Least squares mean change in Positive and Negative Syndrome Scale (PANSS) between at 4 weeks from Mixed Models Repeated Measures (MMRM). The PANSS scale contains 30 questions, each containing an answer range of 1-7. A total PANSS score can range from between 30 to 210; a higher score indicates a worse disease condition
| units on a scale | Aripiprazole Lauroxil | Paliperidone Palmitate |
|---|---|---|
| Least Squares Mean Change in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 4 | -17.3 ± 1.28 | -19.3 ± 1.25 |
Change within treatment groups from baseline Positive and Negative Syndrome Scale (PANSS) and 9 weeks based on the observed data without imputation for missing data. The PANSS scale contains 30 questions, each containing an answer range of 1-7. A total PANSS score can range from between 30 to 210; a higher score indicates a worse disease condition.
| units on a scale | Aripiprazole Lauroxil | Paliperidone Palmitate |
|---|---|---|
| Change in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 9 | -19.8 ± 11.61 | -22.5 ± 13.98 |
Change within treatment groups at baseline Positive and Negative Syndrome Scale (PANSS) and at 25 weeks based on the observed data without imputation for missing data. The PANSS scale contains 30 questions, each containing an answer range of 1-7. A total PANSS score can range from between 30 to 210; a higher score indicates a worse disease condition
| units on a scale | Aripiprazole Lauroxil | Paliperidone Palmitate |
|---|---|---|
| Change in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 25 | -23.3 ± 11.25 | -21.7 ± 14.37 |
Least squares mean change from baseline Positive and Negative Syndrome Scale (PANSS) and 9 weeks from Mixed Models Repeated Measures (MMRM).The PANSS scale contains 30 questions, each containing an answer range of 1-7. A total PANSS score can range from between 30 to 210; a higher score indicates a worse disease condition
| units on a scale | Aripiprazole Lauroxil | Paliperidone Palmitate |
|---|---|---|
| Least Squares Mean Change in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 9 | -18.8 ± 1.33 | -21.5 ± 1.34 |
Least squares mean change in Positive and Negative Syndrome Scale (PANSS) total score at week 25 from Mixed Models Repeated Measures. The PANSS scale contains 30 questions, each containing an answer range of 1-7. A total PANSS score can range from between 30 to 210; a higher score indicates a worse disease condition
| units on a scale | Aripiprazole Lauroxil | Paliperidone Palmitate |
|---|---|---|
| Least Squares Mean Change in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 25 | -22.0 ± 1.42 | -21.1 ± 1.53 |
| Participants | Aripiprazole Lauroxil | Paliperidone Palmitate |
|---|---|---|
| Number of Participants With Serious and Non-serious Adverse Events (AEs) | 69 | 72 |
Collected over Adverse event data was collected over 25 weeks.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Aripiprazole Lauroxil | 0/99 (0%) | 8/99 (8.1%) | 39/99 (39.4%) |
| Paliperidone Palmitate | 0/101 (0%) | 7/101 (6.9%) | 50/101 (49.5%) |
| Event | Aripiprazole Lauroxil | Paliperidone Palmitate |
|---|---|---|
| SchizophreniaPsychiatric disorders | 5/99 | 2/101 |
| Psychotic disorderPsychiatric disorders | 2/99 | 0/101 |
| LeukocytosisBlood and lymphatic system disorders | 1/99 | 0/101 |
| HypercalcaemiaMetabolism and nutrition disorders | 1/99 | 0/101 |
| Generalised tonic-clonic seizureNervous system disorders | 1/99 | 0/101 |
| Suicide attemptPsychiatric disorders | 1/99 | 1/101 |
| Suicidal ideationPsychiatric disorders | 1/99 | 0/101 |
| Renal failureRenal and urinary disorders | 1/99 | 0/101 |
| Alcohol poisoningInjury, poisoning and procedural complications | 0/99 | 1/101 |
| OverdoseInjury, poisoning and procedural complications | 0/99 | 1/101 |
| Event | Aripiprazole Lauroxil | Paliperidone Palmitate |
|---|---|---|
| Injection Site PainGeneral disorders | 17/99 | 25/101 |
| Weight increasedInvestigations | 9/99 | 17/101 |
| AkathisiaNervous system disorders | 9/99 | 11/101 |
| HeadacheNervous system disorders | 8/99 | 8/101 |
| SomnolenceNervous system disorders | 4/99 | 7/101 |
| DystoniaNervous system disorders | 3/99 | 6/101 |
| Age, Continuous(years) | Aripiprazole Lauroxil | Paliperidone Palmitate | Total |
|---|---|---|---|
| Mean | 43.5 ± 9.67 | 43.4 ± 10.83 | 43.4 ± 10.25 |
| Sex: Female, Male(Participants) | Aripiprazole Lauroxil | Paliperidone Palmitate | Total |
|---|---|---|---|
| Female | 26 | 25 | 51 |
| Male | 73 | 76 | 149 |
| Ethnicity (NIH/OMB)(Participants) | Aripiprazole Lauroxil | Paliperidone Palmitate | Total |
|---|---|---|---|
| Hispanic or Latino | 8 | 11 | 19 |
| Not Hispanic or Latino | 91 | 90 | 181 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Aripiprazole Lauroxil | Paliperidone Palmitate | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 2 | 4 | 6 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 72 | 78 | 150 |
| White | 25 | 17 | 42 |
| More than one race | 0 | 2 | 2 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Positive and Negative Syndrome Scale (PANSS) Total Score(units on a scale) | Aripiprazole Lauroxil | Paliperidone Palmitate | Total |
|---|---|---|---|
| Mean | 94.1 ± 9.04 | 94.6 ± 8.41 | 94.4 ± 8.71 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
Ran from Nov 2017 to primary completion in Mar 2019, 15 months.
Results were first posted in Aug 2020, 1 year 4 months after primary completion. A results delay was requested in Apr 2020.
Of 99 industry-sponsored phase 3 interventional studies under Schizophrenia, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 41. This study's 15 months is below that.
Counting every sponsor, half of 113 studies reached it within 32 months; a quarter within 20 and three quarters within 46.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Aripiprazole lauroxil